Building a Common Language: Boehringer Ingelheim Pharma GmbH & Co. KG on Interaction with Regulatory Bodies
In this exclusive interview Dr. Torsten Grünewald - Lead Business Architect at Boehringer Ingelheim Pharma GmbH & Co. KG expresses the need for a common language when interacting with regulatory bodies to make information models such as RIM really work.
Pharma IQ: What are the major challenges today for effectively managing information
for the purpose of regulatory submissions?
T Grünewald: Non-integrated processes in the company and the different requirements p...
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.